Mainstay Lands $108M To Support Launch Of ReActiv8 Back Pain Device
The company has begun the US launch of the ReActiv8 implantable neurostimulator for treating low back pain in the US while expanding commercialization in Australia and Europe.
You may also be interested in...
To open the year, medical device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $7bn.
Mainstay Medical says it will move forward with a US PMA application for its ReActiv8 neuromodulation therapy for chronic back pain even though the ReActiv8 clinical trial failed to reach its primary endpoint.
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the fourth day of the meeting.